Evidence map›Paper›PMID 32808680›Full record

Trial reportAmerican journal of hematology2020

A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Christopher Pleyer, Xin Tian, Shakuntala Rampertaap, Rui Mu, Susan Soto, Jeanine Superata, Erika Gaglione, Clare Sun, Jennifer Lotter, Maryalice Stetler-Stevenson and 7 more

Open access · greenAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Maintenance therapy for chronic lymphocytic leukaemia.The Cochrane database of systematic reviews · 2024
    Review
  3. Review
  4. Targeting Bruton's Tyrosine Kinase in CLL.Frontiers in immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Christopher PleyerHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-9569-9605
Xin TianOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Shakuntala RampertaapHematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Rui MuHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Susan SotoHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Jeanine SuperataHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Erika GaglioneHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-4831-3105
Clare SunHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Jennifer LotterHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Maryalice Stetler-StevensonLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Constance M YuanLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Irina MaricHematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Sergio RosenzweigHematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Thomas FleisherHematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Adrian WiestnerHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Inhye E AhnHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
National Institutes of Health · US

Funding

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapyZIAHL002346 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2009 to 2025
$29.8M
Immunotherapy of low grade lymphoid malignanciesZIAHL006070 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2010 to 2025
$15.9M
FLow Cytometric Detection of Malignant Cells in Body FluidsZICBC011093 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, HAO-WEI · 2009 to 2025
$4.5M
Intramural NIH HHS ZIA HL006070Intramural NIH HHS ZIC BC011093
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAdenineAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleHumansMalePiperidinesSurvival RateVidarabineAdeninefludarabineibrutinibPiperidinesVidarabine

Identifiers

PMID32808680
PMCPMC8932338
OpenAlexW3057829471

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.